Trifecta Capital Advisors LLC Reduces Stake in GRAIL, Inc. $GRAL

Posted by Brian Himes on Jul 12th, 2026

Trifecta Capital Advisors LLC reduced its stake in shares of GRAIL, Inc. (NASDAQ:GRAL – Free Report) by 51.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 8,300 shares of the company’s stock after selling 8,750 shares during the quarter. Trifecta Capital Advisors LLC’s holdings in GRAIL were worth $429,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of GRAL. Fifth Third Bancorp increased its position in shares of GRAIL by 15,733.3% during the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after purchasing an additional 472 shares during the last quarter. N.E.W. Advisory Services LLC purchased a new position in GRAIL during the fourth quarter worth $26,000. Comerica Bank boosted its stake in GRAIL by 59.2% during the third quarter. Comerica Bank now owns 465 shares of the company’s stock worth $27,000 after buying an additional 173 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in GRAIL during the fourth quarter valued at $28,000. Finally, Elyxium Wealth LLC bought a new position in GRAIL during the fourth quarter valued at $31,000.

Analysts Set New Price Targets

A number of equities analysts recently commented on the stock. Guggenheim dropped their price target on shares of GRAIL from $130.00 to $75.00 and set a “buy” rating for the company in a research note on Monday, March 30th. TD Cowen increased their price objective on shares of GRAIL from $65.00 to $69.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Wolfe Research began coverage on shares of GRAIL in a research note on Tuesday, June 2nd. They issued a “peer perform” rating for the company. The Goldman Sachs Group assumed coverage on GRAIL in a research report on Friday, June 5th. They set a “neutral” rating and a $60.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of GRAIL in a report on Tuesday, April 21st. Four investment analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, GRAIL currently has a consensus rating of “Hold” and a consensus price target of $67.00.

Get Our Latest Stock Analysis on GRAL

GRAIL Trading Down 5.0%

Shares of NASDAQ GRAL traded down $3.79 during mid-day trading on Friday, reaching $72.00. The company had a trading volume of 509,860 shares, compared to its average volume of 564,771. The stock has a market cap of $3.09 billion, a price-to-earnings ratio of -6.94 and a beta of 3.22. GRAIL, Inc. has a 52 week low of $29.95 and a 52 week high of $118.84. The business’s 50-day moving average is $64.29 and its 200-day moving average is $70.02.

GRAIL (NASDAQ:GRAL – Get Free Report) last released its quarterly earnings data on Tuesday, May 5th. The company reported ($2.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.76) by $0.47. The company had revenue of $40.78 million during the quarter, compared to analysts’ expectations of $39.16 million. GRAIL had a negative net margin of 253.22% and a negative return on equity of 16.42%. As a group, equities research analysts forecast that GRAIL, Inc. will post -10.91 earnings per share for the current year.

Insider Activity

In related news, insider Andrew John Partridge sold 1,491 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $61.08, for a total value of $91,070.28. Following the completion of the sale, the insider owned 163,738 shares in the company, valued at approximately $10,001,117.04. The trade was a 0.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 1.83% of the company’s stock.

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

Positive Sentiment: No clearly positive company-specific catalysts were reported in the latest batch of articles.
Neutral Sentiment: Several law firms, including Rosen, Berger Montague, Schall, Faruqi & Faruqi, Levi & Korsinsky, and others, are reminding investors about the ongoing class action and the August 4, 2026 lead plaintiff deadline, keeping the legal issue in focus. Article Title
Neutral Sentiment: Robbins LLP and other firms are urging stockholders who bought shares during the alleged class period to contact them for information about joining the lawsuit, suggesting the case is still actively being marketed to affected investors. Article Title
Negative Sentiment: The core negative takeaway is that the lawsuit centers on the February 20, 2026 trial update, which reportedly erased more than $2.2 billion in market value and is now being framed as securities fraud, a headline that can weigh on investor sentiment. Article Title

GRAIL Company Profile

(Free Report)

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.